Dashboard
Manage Tickers

CTLT


()    

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

catalent-q3-eps-006-misses-021-estimate-sales-107b-miss-112b-estimate
Catalent Q3 EPS $(0.06) Misses $0.21 Estim...
05/08/2024 22:25:21

Catalent (NYSE:CTLT) reported quarterly losses of $(0.06) per share which missed the analyst consensus estimate of $0.21 by 128...

siren-biotechnology-and-catalent-partner-to-manufacture-aav-gene-therapies-for-cancer
Siren Biotechnology And Catalent Partner T...
05/08/2024 15:05:04

demand-soars-for-novo-nordisks-weight-loss-drug-wegovy-despite-supply-constraints-and-eli-lilly-competition
Demand Soars For Novo Nordisk's Weight-Los...
05/02/2024 09:48:44

The Danish pharmaceutical company is now shipping more introductory doses of Wegovy to the U.S., as it grapples with supply con...

novo-nordisks-dominance-in-obesity--diabetes-drug-market-backed-by-strong-pipeline-analyst-gives-outperform-rating
Novo Nordisk's Dominance In Obesity & Diab...
04/12/2024 17:22:39

BMO's coverage of Novo Nordisk, spotlighting its groundbreaking advancements in weight loss and diabetes drugs. Analysts fo...

beyond-the-numbers-6-analysts-discuss-catalent-stock
Beyond The Numbers: 6 Analysts Discuss Cat...
04/04/2024 15:01:07

stephens--co-reiterates-equal-weight-on-catalent-maintains-635-price-target
Stephens & Co. Reiterates Equal-Weight on ...
04/04/2024 14:26:35

Stephens & Co. analyst Jacob Johnson reiterates Catalent (NYSE:CTLT) with a Equal-Weight and maintains $63.5 price target.

invenra-to-collaborate-with-catalent-to-co-discover-novel-bispecific-adcs
Invenra To Collaborate With Catalent To Co...
04/02/2024 17:59:04

https://www.businesswire.com/news/home/20240402320363/en/

novo-nordisk-sets-timeframe-for-its-next-gen-experimental-obesity-drug
Novo Nordisk Sets Timeframe For Its Next-G...
03/08/2024 16:12:01

"Novo Nordisk's optimism soars with promising early trial data for amycretin, an experimental weight loss pill. Expect ...

Core News & Articles
Novo Nordisk CFO Says If Catalent Deal Doe...
03/07/2024 16:01:02

Core News & Articles
Novo Nordisk CFO Says If Catalent Deal Doe...
03/07/2024 15:47:42

- Conf Call

escalating-demand-for-obesity-drugs-creates-time-sensitive-race-for-eli-lilly-novo-nordisk
Escalating Demand for Obesity Drugs Create...
03/06/2024 14:33:30

Eli Lilly's strategic collaborations with outsourcing partners for Zepbound (tirzepatide) production. Challenges persist as...

record-high-sp-500-propels-spy-etf-to-500-billion-milestone-nvidia-tops-2-trillion-broadcom-surpasses-tesla
Record-High S&P 500 Propels SPY ETF To $50...
03/01/2024 21:05:12

U.S. stock market continues bull run, hitting record highs for S&P 500 and Nasdaq 100. SPY ETF surpasses $500 billion AUM, ...

top-stocks-not-named-nvidia-you-need-to-know-about-in-2024-heres-what-investors-think-about-them-wall-street-vs-reddit
Top Stocks Not Named Nvidia You Need To Kn...
02/29/2024 21:57:48

Nvidia Corp. is one of the leading top stocks with 60% gain in 2024, but other lesser-known names have outperformed.

ctlt---analyzing-catalents-short-interest
(CTLT) - Analyzing Catalent's Short Interest
02/28/2024 17:30:14

eli-lilly-novo-nordisks-strategies-against-new-weight-loss-drug-competitors
Eli Lilly, Novo Nordisk's Strategies Again...
02/26/2024 16:31:35

Zealand Pharma's drug showed positive results in 83% of patients in Phase 2 trials for MASH, heating up the race for new ob...

in-depth-examination-of-5-analyst-recommendations-for-catalent
In-Depth Examination Of 5 Analyst Recommen...
02/20/2024 19:00:46

rbc-capital-reiterates-sector-perform-on-catalent-maintains-635-price-target
RBC Capital Reiterates Sector Perform on C...
02/20/2024 15:28:19

RBC Capital analyst Sean Dodge reiterates Catalent (NYSE:CTLT) with a Sector Perform and maintains $63.5 price target.

catalent-says-during-3-months-ended-dec-31-2023-extends-restructuring-efforts-to-reduce-costs-headcount-in-biologics--pharma-consumer-health-segments-reduced-headcount-by-about-300-employees-incurred-cumulative-employee-related-charges-of-12m
Catalent Says During 3 Months Ended Dec 31...
02/14/2024 20:21:28

- Reuters

Core News & Articles
Catalent Says Upon Termination Of Merger W...
02/14/2024 20:18:26

- Reuters

nearly-half-of-sp-500-stocks-trade-below-50-day-moving-average-which-one-is-the-cheapest
Nearly Half Of S&P 500 Stocks Trade Below ...
02/14/2024 17:49:15

Nearly half of S&P 500 stocks are below 50-day moving average, indicating poor market breadth. Only top 5 companies shielde...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION